View Item 

Show simple item record

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B

dc.contributor.authorFung, Scott K.en_US
dc.contributor.authorWong, F.en_US
dc.contributor.authorHussain, Maha H. A.en_US
dc.contributor.authorLok, Anna Suk-Fongen_US
dc.date.accessioned2010-06-01T19:44:55Z
dc.date.available2010-06-01T19:44:55Z
dc.date.issued2004-09en_US
dc.identifier.citationFung, S. K.; Wong, F.; Hussain, M.; Lok, A. S. F. (2004). "Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B." Journal of Viral Hepatitis 11(5): 432-438. <http://hdl.handle.net/2027.42/72882>en_US
dc.identifier.issn1352-0504en_US
dc.identifier.issn1365-2893en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72882
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15357648&dopt=citationen_US
dc.format.extent124728 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rights2004 Blackwell Publishing Ltden_US
dc.subject.otherHBV Core Promoter Mutationen_US
dc.subject.otherHBV Precore Mutationen_US
dc.subject.otherHepatitis B Virus Genotypesen_US
dc.subject.otherLamivudine Resistanceen_US
dc.titleSustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis Ben_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Medicine, University of Toronto, Toronto, Ont., Canadaen_US
dc.identifier.pmid15357648en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72882/1/j.1365-2893.2004.00556.x.pdf
dc.identifier.doi10.1111/j.1365-2893.2004.00556.xen_US
dc.identifier.sourceJournal of Viral Hepatitisen_US
dc.identifier.citedreferenceLok AS, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B 2000, Summary of a Workshop. Gastroenterology 2001; 120: 1828 – 1853.en_US
dc.identifier.citedreferenceBrunetto MR, Oliveri F, Rocca G et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198 – 202.en_US
dc.identifier.citedreferenceLaras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepatitis 1998; 5: 241 – 248.en_US
dc.identifier.citedreferenceNaoumov NV, Schneider R, Grotzinger T et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102: 538 – 543.en_US
dc.identifier.citedreferenceGrandjacques C, Pradat P, Stuyver L et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatology 2000; 33: 430 – 439.en_US
dc.identifier.citedreferenceChu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. J Clin Microbiol 1996; 34: 1815 – 1818.en_US
dc.identifier.citedreferenceCarman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588 – 591.en_US
dc.identifier.citedreferenceKramvis A, Kew MC, Bukofzer S. Hepatitis B virus precore mutants in serum and liver of South African blacks with hepatocellular carcinoma. J Hepatology 1998; 28: 132 – 141.en_US
dc.identifier.citedreferenceFunk M, Rosenberg D, Lok A. Worldwide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepatitis 2002; 9: 52 – 61.en_US
dc.identifier.citedreferenceChan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen–negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763 – 768.en_US
dc.identifier.citedreferenceOkamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102 – 8110.en_US
dc.identifier.citedreferenceLindh M, Andersson A, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus – large scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285 – 1293.en_US
dc.identifier.citedreferenceChu C, Hussain M, Lok A. Hepatitis B virus genotype B is associated with earlier spontaneous seroconversion than hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756 – 1762.en_US
dc.identifier.citedreferenceLai CL, Chien RN, Leung NW et al. A one year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Eng J Med 1998; 339: 61 – 68.en_US
dc.identifier.citedreferenceDienstag JL, Schiff ER, Wright TL et al. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. N Engl J Med 1999; 341: 1256 – 1263.en_US
dc.identifier.citedreferenceSanantonio T, Mazzola M, Iacovazzi T et al. Long term follow-up of patients with anti- HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatology 2000; 32: 300 – 306.en_US
dc.identifier.citedreferenceButi M, Cotrina M, Jardi R et al. 2 years of continuous lamivudine in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepatitis 2001; 8: 270 – 275.en_US
dc.identifier.citedreferenceTassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in chronic hepatitis B with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889 – 896.en_US
dc.identifier.citedreferenceHadziyannis, SJ, Papatheodoridis GV, Dimou, E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847 – 851.en_US
dc.identifier.citedreferenceRizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61: 398 – 400.en_US
dc.identifier.citedreferenceTassopoulos NC, Volpes R, Pastore G et al. Post lamivudine treatment follow-up of patients with HBeAg-negative chronic hepatitis B (abstract). J Hepatology 1999; 30 ( suppl 1 ): 117.en_US
dc.identifier.citedreferenceLok ASF, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32:1145 – 1153.en_US
dc.identifier.citedreferenceSchalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562 – 568.en_US
dc.identifier.citedreferencePapatheodoridis G, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis S. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219 – 226.en_US
dc.identifier.citedreferenceBedossa P, Poynard T. for the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289 – 293.en_US
dc.identifier.citedreferencePawlotsky J. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 1554 – 1568.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2893.2004.00556.x.pdf
Size:
121.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.